Achieve Life Sciences Raises Capital, Appoints New CEO

Achieve Life Sciences ( (ACHV) ) has issued an announcement.

On April 15 and 16, 2026, Achieve Life Sciences, Inc. announced a substantial private placement and leadership changes as it advances cytisinicline toward potential approval. The company entered a securities purchase agreement with leading healthcare investors for a private offering of common stock, pre-funded warrants and accompanying warrants, structured at around $3.63 per unit.

The deal is expected to raise about $180 million in upfront gross proceeds, with up to roughly $174 million more if all accompanying warrants are exercised, providing up to $354 million in total financing. Achieve plans to use the capital to fund a Phase 3 trial of cytisinicline for e-cigarette cessation, support commercialization of cytisinicline and bolster working capital, which could significantly strengthen its balance sheet and late-stage pipeline execution.

The financing was led by Frazier Life Sciences, TPG Life Sciences Innovations, venBio Partners, Paradigm BioCapital Advisors and Marshall Wace, alongside other new and existing institutional investors, and is being conducted as a private placement exempt from registration, with resale registration rights granted to investors. Morgan Stanley is acting as sole placement agent, and the company has committed to filing a registration statement to enable future resale of the purchased securities.

In connection with the transaction, Chief Executive Officer and President Richard Stewart notified the board on April 15, 2026 of his decision to step down as principal executive officer effective April 18, 2026, while remaining on the board. The company expects to provide Stewart with severance benefits consistent with his existing employment agreement, underscoring an orderly leadership transition rather than a misconduct-driven departure.

Effective April 18, 2026, the board appointed Andrew D. Goldberg, MD, a physician and experienced healthcare investor, as Chief Executive Officer, President, principal executive officer and a director, marking a strategic shift toward leadership with deep capital markets and life sciences investment expertise. Goldberg’s employment package includes salary, performance-based bonus eligibility and sizable time- and performance-vested equity awards tied to post-financing fully diluted capitalization and ambitious share price milestones.

The equity awards for Goldberg comprise restricted stock units equal to 1% of post-placement fully diluted shares, options for 2%, and performance-based RSUs representing 6.5%, with potential “true up” grants to preserve these ownership percentages, and vesting subject to tenure and stock performance. His severance protections include extended salary and bonus coverage, health benefits and accelerated vesting, with enhanced terms in the event of termination following a change in control, aligning his incentives with long-term shareholder value creation.

Also tied to the private placement, the board on April 15, 2026 appointed new directors Lucian Iancovici and Aaron Royston, designated by TPG Life Sciences Innovations and venBio Partners, effective April 17, 2026. Their addition reflects greater governance influence for cornerstone investors, with Royston receiving standard non-employee director compensation and equity, while Iancovici declined compensation.

Achieve further agreed to add a subsequent director designated by Frazier Life Sciences within 30 days of closing, to nominate these investor-backed directors for re-election at the 2026 and 2027 annual meetings while their sponsors hold at least 5% of outstanding stock, and to reduce the board size to nine directors after the 2026 meeting. This reshaping of the board underscores the growing role of specialist healthcare funds in steering Achieve’s strategic direction as it approaches a key FDA decision for cytisinicline.

The most recent analyst rating on (ACHV) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Achieve Life Sciences stock, see the ACHV Stock Forecast page.

Spark’s Take on ACHV Stock

According to Spark, TipRanks’ AI Analyst, ACHV is a Neutral.

Overall score is weighed down primarily by very weak financial performance (no revenue, sizable losses, and persistent cash burn) and bearish technicals (below key moving averages with negative momentum). The latest earnings call adds support via clear regulatory milestones and clinical/commercial progress, but near-term funding needs and manufacturing quality/supply risks remain significant; valuation signals are limited due to negative earnings and no dividend.

To see Spark’s full report on ACHV stock, click here.

More about Achieve Life Sciences

Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for nicotine dependence, including smoking and e-cigarette cessation. The company’s New Drug Application for cytisinicline for adult smoking cessation was accepted by the U.S. Food and Drug Administration in September 2025, with a PDUFA date set for June 20, 2026.

Cytisinicline, a plant-based alkaloid targeting nicotinic acetylcholine receptors, aims to reduce nicotine cravings and the reward from nicotine products. Achieve is positioning cytisinicline to address both combustible cigarette use and vaping, where there are currently no FDA-approved treatments specifically for e-cigarette cessation, amid significant public health need in the United States and globally.

Average Trading Volume: 671,372

Technical Sentiment Signal: Sell

Current Market Cap: $189M

For an in-depth examination of ACHV stock, go to TipRanks’ Overview page.